GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Price-to-Free-Cash-Flow

Achilles Therapeutics (STU:698) Price-to-Free-Cash-Flow : N/A (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-23), Achilles Therapeutics's share price is €0.79. Achilles Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.42. Hence, Achilles Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Achilles Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:698's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Achilles Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.42. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.42.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -10.70% per year.

During the past 5 years, Achilles Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 42.90% per year. The lowest was -10.70% per year. And the median was 16.10% per year.


Achilles Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Achilles Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Price-to-Free-Cash-Flow Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achilles Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Achilles Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achilles Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's Price-to-Free-Cash-Flow falls into.



Achilles Therapeutics Price-to-Free-Cash-Flow Calculation

Achilles Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.79/-0.416
=N/A

Achilles Therapeutics's Share Price of today is €0.79.
Achilles Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Achilles Therapeutics  (STU:698) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Achilles Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (STU:698) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines